Pharma Focus Asia

Novartis Invests US$541 million (€500 million) in Austria, Europe


Novartis is investing US$541 million (€500 million) to open new biopharmaceutical production in Austria. 


To enhance production capabilities through innovative initiatives, two state-of-the-art cell culture plants are under construction at the established Tyrolean sites in Kundl and Schaftenau. 

A substantial investment of 250 million euros is allocated to the Kundl facility, and is expected to generate 180 highly skilled positions in production, quality assurance, and support services.

In Schaftenau, an investment of approximately another 250 million euros, along with the creation of 165 additional positions in production, quality assurance, and supporting roles, is scheduled for completion this summer 2024.

This new investment aims to establish a production facility boasting the highest output and fostering synergies with existing operations in production, quality control, infrastructure, and support services. 

At the new multifaceted cell culture facility, all production processes are executed by seasoned professionals within a fully compliant cGMP environment. 

The Schaftenau facility is slated for full operational status by summer 2024, while the Kundl facility is projected to commence operations in fall 2025, collectively introducing 350 new high-skilled positions on campus.


Name        Novartis
Type          New Construction
Budget    US$541 million (€500 million)
Year          2024 & 2025

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference